SLG
BIIB icon

Stanley-Laman Group’s Biogen BIIB Stock Holding History

Stanley-Laman Group’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-4,198
Closed -$1.19M – 232
2016
Q4 		$1.19M Buy
4,198
+810
+24% +$240K 0.37% 100
2016
Q3 		$1.06M Sell
3,388
-78
-2% -$23.1K 0.43% 73
2016
Q2 		$838K Buy
+3,466
New +$913K 0.33% 118

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Stanley-Laman Group's BIIB Position: Q1 2017 in Review

Stanley-Laman Group sold out of Biogen (BIIB) in Q1 2017, closing a stake of 4,198 shares — an estimated $1.19M sold.

Stanley-Laman Group first reported a position in BIIB in Q2 2016 and held it in 3 quarters. The position peaked at $1.19M in Q4 2016. 1,019 funds tracked by Wall St. Rank hold BIIB as of Q1 2017.

  • Stanley-Laman Group reported no remaining Biogen position as of Q1 2017 after selling out during the quarter.
  • Stanley-Laman Group sold 4,198 Biogen shares in Q1 2017, an estimated $1.19M.
  • Stanley-Laman Group first reported a position in Biogen in Q2 2016 and held it in 3 quarters.
  • Stanley-Laman Group's Biogen position peaked at $1.19M in Q4 2016.
  • 1,019 funds tracked by Wall St. Rank held Biogen as of Q1 2017.

Based on Stanley-Laman Group's 13F filing for Q1 2017, filed 12 May 2017.